8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 15, 2008

Shire plc

________________________________________________________________________________

(Exact name of registrant as specified in its charter)

Jersey

________________________________________________________________________________

(State or other jurisdiction of incorporation)

0-29630                                                  98-0484822

(Commission File Number)                (IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,

Hampshire RG24 8EP England

________________________________________________________________________________

(Address of principal executive offices)                              (Zip code)

Registrant's telephone number, including area code               44 1256 894 000

________________________________________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.f13e-4(c))

Item 8.01.  Other Events

     Shire plc has issued the press release attached hereto as Exhibit 99.01 which is incorporated by reference herein.

Item 9.01.  Financial Statements and Exhibits

                  (d)  Exhibits.  The following exhibit is filed herewith:

99.01               Press Release dated October 15, 2008

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant  has duly caused  this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE PLC
By:	/s/ A C Russell
Name:    Angus Russell
Title:      Chief Executive Officer

Dated: October 15, 2008

EXHIBIT INDEX
Number	Description
99.01	Press Release dated October 15, 2008

EX-99.1

Exhibit 99.01

Press Release www.shire.com

Third quarter 2008 results date notification – 29 October 2008

Basingstoke, UK – October 15, 2008 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, will announce third quarter 2008 earnings on Wednesday 29 October 2008.

Results press release will be issued at:	12:00 GMT / 08:00 EDT
Investor conference call time:	14:00 GMT / 10:00 EDT

Live conference call for investors:

Angus Russell, Chief Executive Officer and Graham Hetherington, Chief Financial Officer will host the investor and analyst conference call at 14:00 GMT/10:00 EDT.

The details of the conference call are as follows:

UK and International dial in	44 (0)20 7806 1951
US dial in:	1 718 354 1385
Password/Conf ID:	4688205
Live Webcast:*	http://www.shire.com/shire/InvestorRelations/presentations.jsp?tn=2&m1=21

Replay:

A replay of the presentation will be available for two weeks by phone and by webcast for one year.  Details are as follows:

UK and International dial in	44 (0)20 7806 1970
US dial in	1 718 354 1112
Pin code	4688205#
Webcast replay:*	http://www.shire.com/shire/InvestorRelations/presentations.jsp?tn=2&m1=21

* Email verification is required

For further information please contact:

Investor Relations	Souheil Salah (Rest of the World)	+44 1256 894 160
	Ricki Greenwood (North America)	+1 484 595 8517

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX